Exclusive: Nandini Piramal, Chairperson, Piramal Pharma On Q4 Earnings & Growth Plans For FY25

Piramal Pharma Ltd has announced a significant 102.1% year-on-year (YoY) increase in net profit, reaching ₹101.3 crore for the fourth quarter ending March 31, 2024. In comparison, the corresponding quarter saw a net profit of ₹50.1 crore, as per the company's regulatory filing. The company's revenue from operations also saw a notable 18% rise, reaching ₹2,552.4 crore compared to ₹2,163.6 crore in the same period of the previous fiscal year. Additionally, at the operating level, EBITDA surged by 50.9% to ₹529.9 crore in this fiscal quarter, up from ₹351.2 crore in the corresponding period of the preceding fiscal year. Nandini Piramal, Chairperson of Piramal Pharma, discusses the Q4 figures and outlines growth strategies for FY25 in an exclusive interview with Business Today's Sakshi Batra.